關于龍沙（<\/b> Lonza<\/b>）<\/b><\/p> \n
龍沙是全球制藥、生物技術與營養市場的優秀合作伙伴。 我們致力于疾病預防，并通過助力客戶推出創新藥物輔助治療一系列的疾病，促進世界更健康。我們將先進生產制造、科學專業技術、卓越工藝與技術洞察力完美結合以達成目標，幫助客戶在醫療健康領域的發現與創新成果實現商業化。<\/p> \n
1897年，龍沙誕生于瑞士的阿爾卑斯山脈地區。發展至今，業務已遍及全球五大洲。我們擁有約14,000名全職員工，由他們組成的高效團隊及每一名員工都為我們的業務和所在地區及國家做出意義非凡的改變。2020年，公司銷售額達45億瑞士法郎，核心業務的息稅折舊攤銷前利潤（EBITDA）達14億瑞士法郎。更多詳情，請訪問 www.lonza.com<\/a>。<\/p> \n 關于<\/b>Pinteon Therapeutics<\/b><\/p> \n Pinteon Therapeutics正在推進一種新型抗體的臨床研究，旨在中斷毒性Tau的傳播，保護并保留神經退行性病患的腦部功能。Pinteon主打的PNT001是目前在研項目中唯一一款<\/span>靶向cis-pT231 Tau的抗體。cis-pT231 Tau是一種神經毒性表位，已在多項臨床前研究中被證實是引發神經退行性疾病的主要驅動因素之一。Pinteon由Morningside Ventures提供資金支持，擁有一支經驗豐富的管理團隊，并在CNS藥物發現和開發方面擁有優秀的記錄。欲了解更多信息，請訪問pinteon.com<\/a><\/p> \n Lonza Contact Details Victoria Morgan<\/span> Dr. Martina Ribar Hestericová Dirk Oehlers<\/span> Pinteon Therapeutics Contact Details <\/span><\/b><\/p> \n Lisa Qu<\/span><\/b> Additional Information and Disclaimer<\/b><\/p> \n Lonza Group Ltd has its headquarters in Basel, Switzerland<\/span>, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.<\/p> \n Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.<\/p> \n
<\/span><\/b><\/p> \n
<\/b>Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
<\/span>victoria.morgan@lonza.com<\/span><\/a><\/p> \n
<\/b>Trade Media Lead
Lonza Group Ltd
Tel +41 61 316 8982
<\/span>martina.ribarhestericova@lonza.com<\/span><\/a><\/p> \n
<\/b>Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
<\/span>dirk.oehlers@lonza.com<\/span><\/a><\/p> \n
Media contact
Ten Bridge Communications
Tel +1 678-662-9166
<\/span>lqu@tenbridgecommunications.com<\/span><\/a> <\/p> \n